NTLA - Why Intellia Therapeutics Shares Are Trading Higher Monday | Benzinga
Intellia Therapeutics, Inc. (NASDAQ:NTLA) stock is moving higher Monday after the company announced long-term data from its Phase 1 Study of NTLA-2002.
The Details: Intellia’s NTLA-2002 is an experimental CRISPR based gene-editing therapy being developed as a one-time treatment for hereditary angioedema (HAE). The company announced the single dose treatment led to a 98% mean reduction in monthly HAE attacks.
In Phase 1 of the study, patients received single doses of NTLA-2002 between 25 mg and 75 mg via intravenous infusion. HAE attack rates and other data was measured at the start of the ...